Increasing treatment coverage leads to reductions in blood-stage prevalence of both P. falciparum and P. vivax.
First-line treatment of new blood-stage infections with anti-malarial drugs such as chloroquine or ACTs is predicted to cause moderate reductions in blood-stage prevalence of both P. falciparum and P. vivax.
The disease stage, prevalence and types of anaemia were described.
The mean prevalence for CD in the first stage was 0.51/100,000 and 1.42/100,000 for the second stage; the prevalence of CD increased significantly from the first stage to the second stage (p = 0.0003).
For UC, the mean prevalence in the first stage was 2.2/100,000 and 6.12/100,000 for the second stage; the prevalence of UC increased also significantly from the first stage to the second stage (p = 0.0005).
For each canine and second molar, and within each dental maturation stage, the prevalence of the growth phases was calculated.
In stage IV, prevalence of smoking begins to decline for both men and women.
In this stage, the prevalence of circulating parasites varies from 21%to100%0% by using PCR, and this variability may be associated with episodes of reinfection (2 – 4 ).
Tumour stage and prevalence of lymphatic invasion, venous invasion, and LN metastasis were significantly higher in CRCs showing strong SDF-1 α expression than in those with weak expression (Table 2).
This work proposes a population-based model for the estimation of stage-specific prevalence of CRC patients who will require active anti-tumour therapy in a given year.
All the tumors were clinically staged, with a prevalence of stage I patients (54%); 19% of patients were non-smokers (Tables 1– 2).
